CD200 expression predicts poor prognosis in neuroblastoma: a potential biomarker for treatment stratification—a retrospective cohort study
Pediatric Surgery International · 2026
DOI: 10.1007/s00383-026-06294-w ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Pediatric Surgery International, 2026. Verfasst von Yasuhiro Kuroda und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634- 8522, Japan. Hauptthemen laut MEDLINE: Neuroblastoma, Antigens, CD, Biomarkers, Tumor. Die Arbeit nennt 21 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
PURPOSE: High-risk neuroblastomas carry a poor prognosis, and the role of the immunosuppressive glycoprotein CD200 in this disease remains unclear. In this study, we investigated the role of CD200 expression. METHODS: We retrospectively analyzed CD200 expression in 45 neuroblastoma specimens using immunohistochemistry (IHC). Its association with clinicopathological features, patient survival, and tumor-infiltrating lymphocytes (TILs) density was evaluated. Changes in CD200 expression during chemotherapy were examined in the high-risk subgroup. The functional role of CD200 in chemosensitivity was assessed in vitro using siRNA-mediated silencing in SH-SY5Y and IMR-32 neuroblastoma cell lines. RESULTS: High CD200 expression was significantly associated with advanced-stage disease, recurrence, and poor overall survival (5-year OS: 57.3% vs. 100% in low-CD200, p = 0.007). High-CD200 tumors showed significantly reduced infiltration of CD4 + and CD8 + T cells. In high-risk patients, persistently high or increased post-chemotherapy CD200 expression was correlated with 100% recurrence and mortality. In vitro, CD200 silencing significantly enhanced the cytotoxic effects of cisplatin. CONCLUSION: CD200 is a strong negative prognostic biomarker in neuroblastoma, associated with an immunosuppressive tumor microenvironment and chemoresistance. It represents a promising candidate for treatment stratification and a potential therapeutic target for improving outcomes in high-risk patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634- 8522, Japan.
- Department of Pathology, Kobe Children's Hospital, 1-6-7, Minatojimaminamimachi, Chuoku, Kobe, Hyogo, 650-0047, Japan.
- Department of Pediatric Surgery, Kobe Children's Hospital, 1-6-7, Minatojimaminamimachi, Chuoku, Kobe, Hyogo, 650-0047, Japan.
- Department of Surgery, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634- 8522, Japan. m-sho@naramed-u.ac.jp.
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Kuroda, Y., Zuo, S., Terai, T., Miyao, S., Nakamura, K., Kanehiro, H., Yoshida, M., Hatakeyama, T., & Sho, M. (2026). CD200 expression predicts poor prognosis in neuroblastoma: a potential biomarker for treatment stratification—a retrospective cohort study. Pediatric Surgery International. https://doi.org/10.1007/s00383-026-06294-w
Vancouver
Kuroda Y, Zuo S, Terai T, Miyao S, Nakamura K, Kanehiro H, et al. CD200 expression predicts poor prognosis in neuroblastoma: a potential biomarker for treatment stratification—a retrospective cohort study. Pediatric Surgery International. 2026. doi:10.1007/s00383-026-06294-w
BibTeX
@article{Kuroda2026,
author = {Kuroda, Yasuhiro and Zuo, Shogo and Terai, Taichi and Miyao, Shintaro and Nakamura, Kota and Kanehiro, Hiromichi and Yoshida, Makiko and Hatakeyama, Tadashi and Sho, Masayuki},
title = {CD200 expression predicts poor prognosis in neuroblastoma: a potential biomarker for treatment stratification—a retrospective cohort study},
journal = {Pediatric Surgery International},
year = {2026},
doi = {10.1007/s00383-026-06294-w}
}
EUVIMED